|
Objective: To observe the pegylated interferon - 2a ( Pegasys Pegasys , Roche ) in patients with chronic hepatitis B antiviral treatment efficacy, safety and tolerability . Methods: 28 patients with HBeAg-positive chronic hepatitis B patients receiving treatment , subcutaneous injection of pegylated interferon - 2a ( Pegasys Pegasys , Roche ) 180 microg once weekly for 48 weeks , 24 weeks of follow-up , virological response and biochemical response as the primary efficacy response evaluation , while observing the drug treatment of adverse reactions. Results: 28 patients treated , 13 patients with complete response , complete response rate was 46.4% , 11 cases of sustained response , sustained response rate was 39.3% ; 1 patient had anti - HBs , HBsAg negative , when the end of the follow-up remains the same . The end of treatment, 16 patients ( 57.1 % ) ALT returned to normal after discontinuation of two cases ALT increased again , the end of the follow-up there are 20 cases (71.4% ) normalization . Pretreatment ALT level of sustained response was no significant difference ( P gt ; 0.05 ) Efficacy and pre-treatment viral load , low - level viremia ( HBV - DNA lt ; of 10 to 5copies / L ) group the serum of patients with sustained response rate was significantly higher than the high - level viremia ( HBV - DNA gt ; 10 patients with 5copies / L ) group , the former was 70.0 % and the latter 22.2 % , P lt ; 0.05 , there are significant differences , suggesting that baseline viral load will affect the response to treatment . Adverse reactions is mainly manifested in fever , leukopenia , thrombocytopenia , no serious adverse events occurred . Conclusion : polyethylene glycol interferon - 2a ( PEGASYS is PEGASYS , Roche ) in the treatment of chronic hepatitis B antiviral efficacy , safety and tolerability .
|